In castration-sensitive prostate cancer confined to the prostate, is radical prostatectomy combined with orchiectomy superior to radiation combined with androgen deprivation therapy?

Radiation Plus ADT is Superior to Radical Prostatectomy Plus Orchiectomy for Castration-Sensitive Prostate Cancer Confined to the Prostate

For localized castration-sensitive prostate cancer, radiation therapy combined with androgen deprivation therapy (ADT) is the recommended treatment approach, not radical prostatectomy combined with orchiectomy. The combination of surgery plus orchiectomy is not a standard treatment paradigm supported by guidelines or evidence.

Why This Recommendation is Clear

The Fundamental Problem with the Question

The premise of combining radical prostatectomy with orchiectomy for localized disease is not evidence-based. Current guidelines explicitly state:

• Primary ADT alone (including orchiectomy) is not recommended as standard initial treatment of non-metastatic disease 1
• For localized disease, the standard options are radical prostatectomy OR radiotherapy, not surgery combined with castration 1

The Evidence-Based Treatment Paradigm

For truly localized (organ-confined) castration-sensitive prostate cancer, treatment selection depends on risk stratification:

Low-Risk Disease

• Active surveillance is preferred
• If treatment chosen: radical prostatectomy OR radiotherapy alone 1
• No role for ADT/orchiectomy 1

Intermediate-Risk Disease

• Radical prostatectomy OR radiotherapy
• If radiotherapy chosen: consider short-course ADT (4-6 months) as neoadjuvant/concurrent therapy 1
• Still no role for orchiectomy with surgery

High-Risk Localized Disease

This is where radiation + ADT demonstrates clear superiority:

• External beam radiotherapy plus ADT for 2-3 years is the recommended approach 1

• Multiple randomized trials demonstrate survival benefit:

  • SPCG-7: Radical RT improved cause-specific mortality (11.9% vs 23.9%, P<0.001) and overall mortality (29.6% vs 39.4%, P=0.004) 1
  • TROG 96-01: 6 months ADT with RT improved overall mortality (HR 0.63,95% CI 0.48-0.83) 1
  • RTOG 8610: Improved 10-year prostate cancer-specific mortality (23% vs 36%, P=0.01) 1

• Radical prostatectomy plus pelvic lymphadenectomy is listed as an option for highly selected cases only 1, 2

Comparative Outcomes Data

The limited observational data comparing surgery-based vs radiation-based approaches for high-risk disease suggests:

• RT + ADT may offer superior distant metastatic control using modern causal inference frameworks 3
• One SEER-Medicare analysis showed RP + adjuvant RT had improved survival over RT + ADT, but this was not RP + orchiectomy 4
• Toxicity profiles differ significantly: RT + ADT associated with fewer urinary side effects and less treatment regret, though transient hormone-related symptoms occur 3

Why Orchiectomy with Surgery Makes No Sense

1. Orchiectomy is equivalent to medical castration (LHRH agonists), not superior 5, 1

2. For localized disease requiring surgery, adjuvant therapy would be radiotherapy, not castration 6

3. Castration is reserved for:

   • Metastatic disease 7
   • Biochemical recurrence with high-risk features 1
   • As neoadjuvant/adjuvant to radiotherapy in high-risk localized disease 1

4. Adding orchiectomy to surgery for localized disease would expose patients to:

   • Permanent castration side effects (osteoporosis, metabolic syndrome, sexual dysfunction) 5
   • No proven oncologic benefit
   • Violation of treatment guidelines

The Correct Clinical Algorithm

For castration-sensitive prostate cancer confined to the prostate:

1. Risk stratify using PSA, Gleason score, clinical stage
2. Low-risk: Active surveillance preferred; if treatment needed → RP or RT alone
3. Intermediate-risk: RP or RT ± short-course ADT (4-6 months if RT chosen)
4. High-risk localized:
   • Preferred: External beam RT + ADT for 2-3 years 1
   • Alternative: RP + pelvic lymphadenectomy (highly selected cases), with consideration for adjuvant RT if adverse pathology 1, 6

Orchiectomy has no role in the primary treatment of localized prostate cancer, regardless of whether surgery is performed.

Critical Pitfalls to Avoid

• Never combine radical prostatectomy with orchiectomy for localized disease - this is not standard of care
• Do not use primary ADT alone for non-metastatic disease unless patient unsuitable for curative treatment 1
• If performing RP for high-risk disease, plan for potential adjuvant radiotherapy based on pathology, not castration 6
• Medical castration and orchiectomy are equivalent - choice based on patient preference, not efficacy 5